Skip to content

The Relationship Between Fetal Membrane Thickness and Fetal Chromosomal Aneuploidies

The Relationship Between Fetal Membrane Thickness and Fetal Chromosomal Aneuploidies

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06141213
Acronym
PLACE2102
Enrollment
300
Registered
2023-11-21
Start date
2021-10-01
Completion date
2024-08-31
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chromosome Aberrations

Keywords

Fetal membrane, Fetal chromosomal abnormalities, Ultrasound screening

Brief summary

This observational study aims to recruit pregnant women between 18 to 24 weeks of gestation to investigate the relationship between amniotic membrane thickness and fetal chromosomal abnormalities. The primary objectives are to establish whether a correlation exists between the measured thickness of the amniotic membrane and the presence of chromosomal abnormalities in the fetus, and to determine a cutoff value for amniotic membrane thickness that could indicate an increased risk of such abnormalities. Additionally, the study seeks to assess whether the inclusion of amniotic membrane thickness as a biomarker can enhance the detection rate of non-invasive prenatal testing (NIPT) and nuchal translucency (NT) for chromosomal abnormalities.

Interventions

DIAGNOSTIC_TESTUltrasound screening

Ultrasound screening for fetal membrane thickness at 18-24 weeks of pregnancy.

Sponsors

Tianjin Central Hospital of Gynecology Obstetrics
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

1. Singleton pregnant women between 18-24 weeks of gestation. 2. Participants with high-risk indications for prenatal fetal chromosomal abnormalities, including: * Nuchal translucency (NT) ≥ 3 mm. * High-risk results from non-invasive prenatal testing (NIPT) using cell-free fetal DNA from peripheral maternal blood. * Ultrasound-detected fetal abnormalities. * Other indicators include adverse birth histories, parental chromosomal abnormalities, familial diseases, and a history of thyroid cancer post-surgery. 3. Gestational age and estimated due date were confirmed by the first day of the last menstrual period and adjusted using fetal crown-rump length measured during the first-trimester ultrasound scan. 4. Participants who provided written informed consent for amniocentesis. \-

Exclusion criteria

1. Women with multiple pregnancies or higher-order births. 2. Previous chorionic villus sampling or amniocentesis in the current pregnancy. 3. Gestational age at the time of amniocentesis greater than 25 weeks or less than 18 weeks. 4. Presence of amniotic band syndrome. 5. The presence of uterine anomalies or conditions may impact ultrasound measurements' reliability. 6. Any medical condition or obstetric complication that, in the opinion of the investigators, might pose a risk to the participant or interfere with the study outcomes.

Design outcomes

Primary

MeasureTime frameDescription
Correlation Between Fetal Membrane Thickness and Chromosomal AbnormalitiesMarch, 2024The difference in mean fetal membrane thickness between the normal and abnormal chromosomal groups, and the establishment of a threshold value for risk assessment.

Countries

China

Contacts

Primary ContactJiasong Cao, PhD
caojiasong@hotmail.com+86 13662046469

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026